FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321764925> ?p ?o ?g. }

• W4321764925 abstract "Abstract Background The performance of rapid antigen tests for SARS-CoV-2 (Ag-RDT) in temporal relation to symptom onset or exposure is unknown, as is the impact of vaccination on this relationship. Objective To evaluate the performance of Ag-RDT compared with RT-PCR based on day after symptom onset or exposure in order to decide on ‘when to test’. Design, Setting, and Participants The Test Us at Home study was a longitudinal cohort study that enrolled participants over 2 years old across the United States between October 18, 2021 and February 4, 2022. All participants were asked to conduct Ag-RDT and RT-PCR testing every 48 hours over a 15-day period. Participants with one or more symptoms during the study period were included in the Day Post Symptom Onset (DPSO) analyses, while those who reported a COVID-19 exposure were included in the Day Post Exposure (DPE) analysis. Exposure Participants were asked to self-report any symptoms or known exposures to SARS-CoV-2 every 48-hours, immediately prior to conducting Ag-RDT and RT-PCR testing. The first day a participant reported one or more symptoms was termed DPSO 0, and the day of exposure was DPE 0. Vaccination status was self-reported. Main Outcome and Measures Results of Ag-RDT were self-reported (positive, negative, or invalid) and RT-PCR results were analyzed by a central laboratory. Percent positivity of SARS-CoV-2 and sensitivity of Ag-RDT and RT-PCR by DPSO and DPE were stratified by vaccination status and calculated with 95% confidence intervals. Results A total of 7,361 participants enrolled in the study. Among them, 2,086 (28.3%) and 546 (7.4%) participants were eligible for the DPSO and DPE analyses, respectively. Unvaccinated participants were nearly twice as likely to test positive for SARS-CoV-2 than vaccinated participants in event of symptoms (PCR+: 27.6% vs 10.1%) or exposure (PCR+: 43.8% vs. 22.2%). The highest proportion of vaccinated and unvaccinated individuals tested positive on DPSO 2 and DPE 5-8. Performance of RT-PCR and Ag-RDT did not differ by vaccination status. Ag-RDT detected 78.0% (95% Confidence Interval: 72.56-82.61) of PCR-confirmed infections by DPSO 4. For exposed participants, Ag-RDT detected 84.9% (95% CI: 75.0-91.4) of PCR-confirmed infections by day five post-exposure (DPE 5). Conclusions and Relevance Performance of Ag-RDT and RT-PCR was highest on DPSO 0-2 and DPE 5 and did not differ by vaccination status. These data suggests that serial testing remains integral to enhancing the performance of Ag-RDT." @default.
• W4321764925 created "2023-02-25" @default.
• W4321764925 creator A5003631214 @default.
• W4321764925 creator A5006791475 @default.
• W4321764925 creator A5007828699 @default.
• W4321764925 creator A5008107426 @default.
• W4321764925 creator A5008975117 @default.
• W4321764925 creator A5011685760 @default.
• W4321764925 creator A5011977016 @default.
• W4321764925 creator A5017527636 @default.
• W4321764925 creator A5017773903 @default.
• W4321764925 creator A5017957584 @default.
• W4321764925 creator A5026659821 @default.
• W4321764925 creator A5027695598 @default.
• W4321764925 creator A5030511174 @default.
• W4321764925 creator A5031462263 @default.
• W4321764925 creator A5039539954 @default.
• W4321764925 creator A5041036157 @default.
• W4321764925 creator A5045061206 @default.
• W4321764925 creator A5050411008 @default.
• W4321764925 creator A5052539701 @default.
• W4321764925 creator A5059167713 @default.
• W4321764925 creator A5065680486 @default.
• W4321764925 creator A5066589212 @default.
• W4321764925 creator A5071695607 @default.
• W4321764925 creator A5074292303 @default.
• W4321764925 creator A5074533872 @default.
• W4321764925 creator A5077905008 @default.
• W4321764925 creator A5077971003 @default.
• W4321764925 creator A5078716241 @default.
• W4321764925 creator A5080710145 @default.
• W4321764925 creator A5081586131 @default.
• W4321764925 creator A5081943007 @default.
• W4321764925 creator A5082256162 @default.
• W4321764925 creator A5082960906 @default.
• W4321764925 creator A5083581553 @default.
• W4321764925 creator A5087269024 @default.
• W4321764925 creator A5089836483 @default.
• W4321764925 creator A5090096143 @default.
• W4321764925 creator A5091056312 @default.
• W4321764925 creator A5091064969 @default.
• W4321764925 date "2023-02-24" @default.
• W4321764925 modified "2023-10-02" @default.
• W4321764925 title "Performance of Rapid Antigen Tests Based on Symptom Onset and Close Contact Exposure: A secondary analysis from the Test Us At Home prospective cohort study" @default.
• W4321764925 cites W2020018978 @default.
• W4321764925 cites W3010233963 @default.
• W4321764925 cites W3120052220 @default.
• W4321764925 cites W3127899647 @default.
• W4321764925 cites W3132070651 @default.
• W4321764925 cites W3152490217 @default.
• W4321764925 cites W3165605711 @default.
• W4321764925 cites W3173352863 @default.
• W4321764925 cites W3192950354 @default.
• W4321764925 cites W3193784398 @default.
• W4321764925 cites W3195990721 @default.
• W4321764925 cites W4212877109 @default.
• W4321764925 cites W4220921782 @default.
• W4321764925 cites W4225131924 @default.
• W4321764925 cites W4226391429 @default.
• W4321764925 cites W4226530665 @default.
• W4321764925 cites W4283718348 @default.
• W4321764925 cites W4290039435 @default.
• W4321764925 cites W4290087601 @default.
• W4321764925 cites W4292622968 @default.
• W4321764925 cites W4296686923 @default.
• W4321764925 cites W4304114234 @default.
• W4321764925 cites W4304114401 @default.
• W4321764925 doi "https://doi.org/10.1101/2023.02.21.23286239" @default.
• W4321764925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36865199" @default.
• W4321764925 hasPublicationYear "2023" @default.
• W4321764925 type Work @default.
• W4321764925 citedByCount "0" @default.
• W4321764925 crossrefType "posted-content" @default.
• W4321764925 hasAuthorship W4321764925A5003631214 @default.
• W4321764925 hasAuthorship W4321764925A5006791475 @default.
• W4321764925 hasAuthorship W4321764925A5007828699 @default.
• W4321764925 hasAuthorship W4321764925A5008107426 @default.
• W4321764925 hasAuthorship W4321764925A5008975117 @default.
• W4321764925 hasAuthorship W4321764925A5011685760 @default.
• W4321764925 hasAuthorship W4321764925A5011977016 @default.
• W4321764925 hasAuthorship W4321764925A5017527636 @default.
• W4321764925 hasAuthorship W4321764925A5017773903 @default.
• W4321764925 hasAuthorship W4321764925A5017957584 @default.
• W4321764925 hasAuthorship W4321764925A5026659821 @default.
• W4321764925 hasAuthorship W4321764925A5027695598 @default.
• W4321764925 hasAuthorship W4321764925A5030511174 @default.
• W4321764925 hasAuthorship W4321764925A5031462263 @default.
• W4321764925 hasAuthorship W4321764925A5039539954 @default.
• W4321764925 hasAuthorship W4321764925A5041036157 @default.
• W4321764925 hasAuthorship W4321764925A5045061206 @default.
• W4321764925 hasAuthorship W4321764925A5050411008 @default.
• W4321764925 hasAuthorship W4321764925A5052539701 @default.
• W4321764925 hasAuthorship W4321764925A5059167713 @default.
• W4321764925 hasAuthorship W4321764925A5065680486 @default.
• W4321764925 hasAuthorship W4321764925A5066589212 @default.
• W4321764925 hasAuthorship W4321764925A5071695607 @default.
• W4321764925 hasAuthorship W4321764925A5074292303 @default.
• W4321764925 hasAuthorship W4321764925A5074533872 @default.
• W4321764925 hasAuthorship W4321764925A5077905008 @default.
• W4321764925 hasAuthorship W4321764925A5077971003 @default.

• next